Search clinical trials for: NOL+monitoring
Total 0 results
Nothing found
Sponsors and Collaborators
- Belfast Arthroplasty Research Trust (BART)
- Universität Tübingen
- José Castro
- GTEI
- Castleton University
- University of Valladolid
- MB Clinical Research, LLC
- Fabian Rohner
- Damagen Genetic Diagnostic Center
- Crowley Carter Foundation
- Plymouth University Peninsula Schools of Medicine & Dentistry (PUPSMD)
- Shanghai IxCell Biotechnology Co., LTD
- Hospital Sirio-Libanes Ensino e Pesquina
- Mexican Emerging Infectious Diseases Clinical Research Network
- Don Cockcroft
- Narhalsan primary care rehabilitation
- Junta de Andalucía - Consejería de Salud y Familias, Spain
- Bon Secours Pediatric Dental Associates
- Department of Cardiology, Lausanne University Center Hospital, Lausanne, Switzerland
- Biotics, Inc.
- View Full List
Medical Conditions
- Diabetic Kidney Disease (DKD)
- Prostate Specific Antigens
- Support Program
- Genome-wide High Throughput Sequencing
- Multimodal Ultrasonographic Assessment of Axillary Lymph Nodes in Patients With Breast Cancer
- Retention of 3D Printed Dentures
- Malignant Neoplasms of Female Genital Organs
- Bulging of Vaginal Wall
- Unintentional Ingestion of Drugs Contained Within Prescription Vials and Blisters.
- Nerve Entrapments
- Shared Decision Making
- FLT3-ITD
- Gastrointestinal Stromal Tumor of Stomach
- Vagus Nerve Injuries
- Opiate Dependent Patients Who Are Undergoing Inpatient Detoxification in Singapore
- Rejection Acute Hepatic
- To Contribute to a Better Control of COVID-19 in Children in Niger
- Disturbance of Attention
- Confirmed Diagnosis of Cystic Fibrosis
- Tracheal Dilatation
- View Full List
Drug Interventions
- Lidocaine, epinephrine (Local anesthetic)
- ABT-199
- PEP005 Gel
- Fluorescein + ALA
- Trimetazidine 35 mg
- Granulocyte colony-stimulating factor (G-CSF)
- Azacitidine
- Etanercept
- Metoprolol succinate sustained-release tablet
- Fluorouracil
- Cabozantinib
- Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase
- ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle
- Sulfasalazine
- PF-05212384
- Quadratus Lumborum Block type 2
- SNAC
- Axitinib plus toripalimab
- Dapagliflozin
- Gliadel Wafer
- View Full List
CROs by country
- Contract Research Organizations in Australia
- Contract Research Organizations in Bulgaria
- Contract Research Organizations in France
- Contract Research Organizations in Guinea
- Contract Research Organizations in Kenya
- Contract Research Organizations in Liberia
- Contract Research Organizations in Madagascar
- Contract Research Organizations in Mali
- Contract Research Organizations in Moldova
- Contract Research Organizations in Qatar
- Contract Research Organizations in Slovakia
- Contract Research Organizations in Switzerland
- Contract Research Organizations in Ukraine
- CRO list by country